Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in…
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
– RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy –…
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma…
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s…
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…